Research Advances

Blog Post

Santhera Pharmaceuticals Announces Publication of Positive Long-Term Results from Retrospective Study of Idebenone in DMD

By Jeanene Swanson | December 18, 2019
MDA logo
Blog Post

Solid Biosciences Releases Letter to DMD Community Announcing Update on IGNITE DMD Trial, Resolution of Serious Adverse Event

By MDA Staff | December 18, 2019
Illustration of DNA
Blog Post

FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | December 13, 2019
Blog Post

FDA Approves Aquestive Therapeutics’ Exservan for the Treatment of ALS

By Jeanene Swanson | December 6, 2019
Blog Post

Kadimastem Announces Positive Interim Results from Phase 1/2a Study of AstroRx in ALS

By Jeanene Swanson | December 5, 2019
Illustration of DNA
Blog Post

FDA Accepts Roche Genentech’s NDA for Risdiplam for the Treatment of SMA

By Jeanene Swanson | December 3, 2019
Blog Post

Zogenix Announces Positive Results from Pivotal Study of Investigational Treatment MT1621 for TK2 Deficiency

By Jeanene Swanson | December 2, 2019
Blog Post

Roche Genentech Announces Positive Results from Pivotal Study of Risdiplam in SMA Types 2 and 3

By Jeanene Swanson | November 15, 2019
Blog Post

NS Pharma Submits New Drug Application to FDA for Viltolarsen to Treat DMD Amenable to Exon 53 Skipping

By Jeanene Swanson | October 7, 2019
MDA logo
Blog Post

In a Letter to the Duchenne Community, Santhera Announces Positive Results of Phase 2 Vamorolone Study, EMA’s Review of Puldysa to Treat Symptoms of DMD

By MDA Staff | September 26, 2019